FDA Asks Allergan to Voluntarily Recall Breast Implants to Protect Against Rare Cancer
July 24th 2019The Food and Drug Administration has requested that the manufacturer voluntarily recall certain breast implants and tissue expanders from the market to protect women from risks such as breast implant-associated anaplastic large cell lymphoma.
Read More
FDA Approves Zirabev, an Avastin Biosimilar, for Five Cancer Types
June 28th 2019The FDA has approved Zirabev, a biosimilar to Avastin, for the treatment of five types of cancer: colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Read More
Despite Advantages, Disparities in Access to Palliative Care in Kidney Cancer Remain
June 19th 2019Although palliative care has been shown to improve survival rates among patients with metastatic renal cell carcinoma, its utilization remains low while certain barriers and disparities still exist.
Read More
Opdivo Plus Radiation Fails to Prolong Survival in Subtype of Glioblastoma
May 9th 2019The phase 3 CheckMate 498 trial, designed to compare Opdivo with Temodal for the treatment of patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme failed to meet its primary endpoint of increasing overall survival.
Read More
FDA Approves Kadcyla for Adjuvant Treatment of Patients With HER2-Positive Early Breast Cancer
May 4th 2019The FDA approved Kadcyla for adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin-based treatment.
Read More